Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?

Article

Abstract: The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 mon

Palabras claves:

CD20, Pharmacogenomics, Rheumatoid Arthritis, rituximab, Sjögren's syndrome, systemic lupus erythematosus

Autores:

Anaya J.M., Claudio Galarza, Mantilla R.D., Pineda-Tamayo R., Rojas-Villarraga A., Rueda J.C., Tobón G.J., Valencia D., Zurita L.

Fuentes:

scopus